💊Pembrolizumab in addition to Dabrafenib/Trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma
Thyroid Journal

✅Pembrolizumab added upfront or at progression vs dabra-trame alone
mOS: 17 vs 9 mo, p=0.03
mPFS: 11 vs 4 mo, p=0.04
✅If dabra-trame given as neoadjuvant,…

😊The beauty of precision Oncology

48yo M
Metastic Melanoma w/ BRAF mutation

💊1L Ipi + Nivo (progression dis)

🧬2L: Dabrafenib + Trametinib (BRAF + MEK)

☢️PET/CT: impressive complete response after 6mo of target therapy

#radres #FOAMrad #oncology

15 days away from the anniversary of my daughter's '16 Dx of stg4 melanoma. She was weeks from dying.
Here we are beginning YEAR SEVEN!
I am so grateful to Docs, nurses, NPs, physical therapists, dabrafenib, mekinist & keytruda for saving her life. She lost a leg, but thrives.❤️

#dcvax $nwbo #gbm

Thought this statement was interesting from the recent NICE recommendation:

'The company has a confidential commercial arrangement for each medicine through a simple discount patient access scheme which makes dabrafenib plus trametinib available to the NHS…

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia ashpublications.org/blood/article-… dual targeted therapy for RR HCL. 2 yrs OS up to 95%.

T:👉Güzel haber…

Bu faz 2 çalışmasında* BRAF V600 mutasyonları taşıyan düşük dereceli glioma (beyin tümörü) hastası olan, daha önce hiç tedavi almamış çocuk hastalar rastgele iki gruba ayrıldı. Bir grup “akıllı ilaçlardan” dabrafenib ve trametinib alırken diğer grup standart…

NICE approve 1L Dabrafenib & Trametinib for BRAF V600E NSCLC

Dabrafenib/Trametinib for BRAF V600E Solid Tumors Vivek Subbiah, MD

Impressive results for dabrafenib + trametinib in children with BRAF-V600 glioma, but haven't we reached consensus that waterfall plots should have the patients with progression on the left? ascopubs.org/doi/full/10.12…

TEBRP GÜNCELLENDİ

TEBRP SUT Kontrol Uygulamalarına;
•Aksitinib
•Dabrafenib
•Setuksimab
•Kenodeoksikolik asit
•İksazomib
etkin maddelerinin SUT Kontrol Uygulamaları eklendi.
Web ve Mobil uygulamamızda, bu etkin maddeleri içeren müstahzarların SUT Özet sekmelerinden veya ana…

📢 #EspecialistasTiroides : Asistan a nuestra presentación 🗓️ Vie 5/5, 8am EST 🕗 sobre el estudio 🔬 de la Dra. Sophie Leboulleux en el Ensayo de Rediferenciación con Dabrafenib-Trametinib y 131-I en Cáncer de Tiroides Metastásico. ⚕️🦋 #MedTwitter #Endotwitter

Dabrafenib & trametinib in BRAF V600E/R BRAF mutated solid tumours
eClinicalMedicine – The Lancet Discovery Science
doi.org/10.1016/j.ecli…
🔎BELIEVE phs II, 50 pts, 7 tumor types incl CCC
👉ORR 28%, DCR 84%, PFS 6.5 mo, mOS 9.7 mo
🧐within expectations, additional line for pts w/ limited options
ESMO - Eur. Oncology…

Solo 15 días de tratamiento con dabrafenib + trametinib en una paciente con un tumor anaplásico de tiroides V600E positivo

This Friday @ 8 AM EDT, we are thrilled to have Dr. Camille Buffet from Hôpital Pitié Salpêtrière - AP-HP present her publication: Detection of BRAFV600E by Digital PCR on Fine-needle Aspirate Enables Rapid Initiation of Dabrafenib and Trametinib in Unresectable Anaplastic Thyroid Carcinoma

Glad to contribute with Dr Vivek Subbiah, MD to the 2023 ASCO Educational Book by discussing the tissue-agnostic use of #dabrafenib plus #trametinib in patients with #BRAF V600E mutated cancers!
Now published online at: ascopubs.org/doi/abs/10.120…

The FDA has approved the use of dabrafenib (Tafinlar, Novartis) with trametinib (Mekinist, Novartis) for some pediatric patients 1 year of age and older with low-grade glioma that have a BRAF V600E mutation. (1/2)

📢 ¡Esta semana en TIRO x MDs, estamos emocionados de recibir a Naifa Busaidy!

Explora su trabajo sobre opciones de tratamiento para el #CáncerDeTiroides Refractario a Radioyodo. No te pierdas sus conocimientos sobre los resultados del ensayo Dabrafenib vs. Dabrafenib +…

🎯Promising efficacy and safety of dabrafenib (BRAF inhibitor) & trametinib (MEK inhibitor) combo for patients with BRAFV600E-mutated advanced rare cancers.
🎯High overall response rates and manageable side effects suggest a potential treatment approach. #precisionmedicine AACR…

Just published!
The results of the Phase 2 study (BELIEVE study; NCCH1901) of dabrafenib-trametinib combination therapy across cancer types in Japan have just been published in eClinicalMedicine part of the Lancet discovery science. #presicionmedicine

sciencedirect.com/science/articl…

For the 1st time a #treatment of pediatric patients (1+ yrs old) with low-grade glioma and BRAF V600E mutation was approved by U.S. FDA last month. It is a combination of dabrafenib (PDB 4xv2) with trametinib (PDB 7m0y). #cancer